Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 5/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26221717 | 0.84 | STAT3 (0.75) | STAT3 | |
| SCHEMBL22525771 | 0.84 | STAT3 (0.75) | STAT3 | |
| SCHEMBL26222062 | 0.84 | STAT3 (0.75) | STAT3 | |
| SCHEMBL31366734 | 0.82 | SLC6A2 (0.55) | NTSR1NTSR2SLC6A2KISS1RNMUR2 | |
| SCHEMBL31239092 | 0.82 | NMUR2 (0.57) | NTSR1NTSR2SORT1NMUR2NMUR1 | |
| SCHEMBL8521204 | 0.81 | SLC6A2 (0.56) | NTSR1NTSR2SLC6A2SORT1NMUR2 | |
| SCHEMBL8441486 | 0.81 | KDM1A (0.54) | NTSR1NTSR2KISS1RNMUR2NMUR1 | |
| SCHEMBL30906513 | 0.81 | RAMP3 (0.55) | NTSR1NMUR2NMUR1 | |
| SCHEMBL31130572 | 0.81 | SLC6A2 (0.55) | NTSR1NTSR2SLC6A2SORT1KISS1R | |
| SCHEMBL30563280 | 0.81 | SLC6A2 (0.52) | NTSR1NTSR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712974-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709370-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12509530-B2 | Single domain antibodies directed against intracellular antigens | Singh Moelcular Medicine, LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025103477-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2025-05-22 | — | — | WO | disclosed |
| CN-111548344-B | STAT3 small molecule inhibitor and application thereof | 北京深度制耀科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119301127-A | 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions | 瑞克鲁迪克斯制药股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119183453-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-117756725-A | Hydrazine substituted phenyl quinazoline compound, preparation method and anti-tumor application thereof | 西北工业大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117658852-A | Substituted phenoxyacethydrazide compound, preparation method thereof and application of substituted phenoxyacethydrazide compound as STAT3 anti-inflammatory inhibitor | 西北工业大学 | 2024-03-08 | — | — | CN | disclosed |
| US-20230286919-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN THERAPY | SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (CN) | 2023-09-14 | — | — | US | disclosed |
| CN-111848793-B | Single domain antibodies against intracellular antigens | 辛格生物技术有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-4125901-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN THERAPY | Vestlandets Innovasjonsselskap AS (NO) | 2023-02-08 | — | — | EP | disclosed |
| US-20220396637-A1 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS | SINGH MOLECULAR MEDICINE, LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11370847-B2 | Single domain antibodies directed against intracellular antigens | SINGH MOLECULAR MEDICINE, LLC (US) | 2022-06-28 | — | — | US | disclosed |
| EP-4006052-A1 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS | Singh Molecular Medicine, LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220089783-A1 | METHODS OF USING SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EBOLA VIRUS | SINGH BIOTECHNOLOGY, LLC (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | STAT3 2/4885NTSR1 1819/4885NTSR2 2286/4885 |
| US-12509530-B2 | Single domain antibodies directed against intracellular antigens | STAT3, STAT5B, STAT5A | STAT3 1/4885NTSR1 4013/4885NTSR2 4175/4885 |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | STAT3 2/4885NTSR1 2918/4885NTSR2 3033/4885 |
| US-20230286919-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN THERAPY | STAT3, STAT1, STAT4 | STAT3 1/4885NTSR1 1827/4885NTSR2 1673/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | STAT3 2/4885NTSR1 2805/4885NTSR2 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.